Definium Therapeutics, Inc. (DFTX) Stock Analysis — Probabli.AI
AI-powered analysis for DFTX (Definium Therapeutics, Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. AI consensus: Bullish.
Last price: $36.18 · Market cap: $2.7B · AI consensus: Bullish
Definium Therapeutics, Inc. (DFTX) is positioned for substantial short-term growth with promising phase 3 trial results, a significant collaboration with a pharma giant, and a strong 'strong buy' analyst consensus pointing towards potential stock appreciation. Despite facing challenges like earnings surprises and patent disputes, its innovative drug pipeline and strategic partnerships create…
Probabilistic 1-Year Outlook
- Bull 5500% · Neutral 2500% · Bear 2000%
- Definium Therapeutics has shown potential for rapid short-term appreciation due to significant positive news, including promising phase 3 results and a major collaboration deal. Despite a history of missing earnings…
5-Year Outlook
- Bull 6000% · Neutral 2000% · Bear 2000%
SWOT Highlights
- Strength: Promising phase 3 trial results
- Strength: Strong collaborations with major pharma companies
- Risk: Consistent earnings misses
- Risk: Negative average EPS surprise
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
15 Wall Street analysts rate DFTX a STRONG BUY with a mean price target of $48.54.
Analysis generated Jun 24, 2026 · Model: gpt-4o. Run a fresh analysis on probabli.xyz/stock/DFTX.
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.